玖玖资源网站,爆乳久久久,日韩精品乱码久久久蜜桃,精品呦国产一区二区三区,国产伦高清一区二区三区,sese一区二区,午夜精品福利一区二区三区,三级黄色网站久久免费

首頁
訂購/客服:400-666-5481

TAK-285

    
99.0%

N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide

源葉(MedMol)
S81040 一鍵復(fù)制產(chǎn)品信息
871026-44-7
C26H25ClF3N5O3
547.96
TAK285, TAK285, TAK 285
貨號 規(guī)格 價(jià)格 上海 北京 武漢 南京 購買數(shù)量
S81040-5mg
99.0% ¥1020.00 5 - - -
S81040-10mg
99.0% ¥1700.00 6 - - -
S81040-25mg
99.0% ¥3230.00 6 - - -
S81040-100mg
≥99% ¥7800.00 貨期:2-3天 - - -
產(chǎn)品介紹 參考文獻(xiàn) 質(zhì)檢證書(COA) 摩爾濃度計(jì)算器 相關(guān)產(chǎn)品

產(chǎn)品介紹

TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1.

產(chǎn)品描述: TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1.
靶點(diǎn): MEK;HER;Aurora Kinase;EGFR;EGFR;?MEK;?HER;?AuroraKinase
體外研究: Among the 34 kinases tested, TAK-285 only significantly inhibits HER4 with IC50 of 260 nM,slightly inhibits MEK1, MEK5, c-Met, Aurora B, Lck, CSK, and Lyn B with IC50 of 1.1 μM,5.7 μM, 4.2 μM, 1.7 μM, 2.4 μM, 4.7 μM, and 5.2 μM, respectively, and displays noactivity against other kinases with IC50 of >10 μM. TAK-285 shows significant growth inhibitory activity against BT-474 cells (HER2-overexpressing human breast cancer cell line) with GI50 of 17 nM. Compared with SYR127063 a potent inhibitor of HER2, TAK-285 displays similar in vitro potency against HER2 and EGFR. Compared with the full cytoplasmic domains of the wild-type proteins, the mutations and shortened boundaries used for structure determination of HER2-KD and EGFR-KD do not significantly change the inhibitory activity (IC50) of TAK-285. TAK-285 binds to the inactive conformation of EGFR, and shows a similar binding mode with lapatinib in the active site.
體內(nèi)研究: The oral bioavailability of TAK-285 is 97.7% in rats and 72.2% in mice at a dose of 50 mg/kg. Oral administration of TAK-285 at 100 mg/kg twice daily for 14 days displays significant antitumor efficacy in the HER2-overexpressing BT-474 tumor xenograft mouse model with tumor/control (T/C) ratio of 29%, without affecting body weight. Similar to the BT-474 model, TAK-285 exhibits dose-dependent tumor growth inhibition of 4-1ST (HER2-overexpressing human gastric cancer tumor) xenografts in mice, with T/C of 44% and 11% at doses of 50 mg/kg and 100 mg/kg, twice daily, respectively, without significant body weight loss in mice. Furthermore, TAK-285 treatment induces dose-dependent growth inhibition of 4-1ST tumors in rats with T/C of 38% and 14% at doses of 6.25 mg/kg and 12.5 mg/kg, and, particularly noteworthy, tumor regression with T/C of -12% and -16% at doses of 25 mg/kg and 50 mg/kg, respectively. After oral administration of TAK-285, a significant amount of TAK-285 is present in the brain of rats in pharmacologically active, unbound form (approximately 20% of its free plasma level), indicating that TAK-285 has a potential in the therapy of CNS malignancies/metastases.
細(xì)胞實(shí)驗(yàn): The cells are treated continuously with various concentrations of TAK-285 for 5 days. The live cell numbers are counted with a particle analyzer.(Only for Reference)
參考文獻(xiàn): 1. Aertgeerts K, et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem, 2011, 286(21), 18756-18765. 2. Ishikawa T, et al. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J Med Chem, 2011, 54(23), 8030-8050. 3. Erdo F, et al. Verification of brain penetration of the unbound fraction of a novel HER2/EGFR dual kinase inhibitor (TAK-285) by microdialysis in rats. Brain Res Bull, 2012, 87(4-5), 413-419.
溶解性: Soluble  in  DMSO、Ethanol
保存條件: -20℃
配置溶液濃度參考:
1mg 5mg 10mg
1 mM 1.825 ml 9.125 ml 18.25 ml
5 mM 0.365 ml 1.825 ml 3.65 ml
10 mM 0.182 ml 0.912 ml 1.825 ml
50 mM 0.036 ml 0.182 ml 0.365 ml
注意: 部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。

參考文獻(xiàn)

質(zhì)檢證書(COA)

如何獲取質(zhì)檢證書(COA)?
請輸入貨號和一個(gè)與之匹配的批號。
例如:
批號:JS298415 貨號:S20001-25g
在貨品標(biāo)簽上如何找到貨號和批號?

摩爾濃度計(jì)算器

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

=
×
×
主站蜘蛛池模板: 灵璧县| 土默特右旗| 南阳市| 仙居县| 鄯善县| 南城县| 新沂市| 英超| 响水县| 凉城县| 楚雄市| 孝感市| 新密市| 扎赉特旗| 陈巴尔虎旗| 托里县| 七台河市| 紫金县| 龙南县| 柘荣县| 安泽县| 涞水县| 澎湖县| 江油市| 平陆县| 汨罗市| 盐山县| 林州市| 武定县| 错那县| 娱乐| 汤阴县| 丹东市| 呼图壁县| 侯马市| 常德市| 邹城市| 东源县| 遵义县| 宜君县| 吐鲁番市|